Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Authors

Laurie S Conklin, George Washington University
Jesse M Damsker
Eric P Hoffman
William J Jusko
Panteleimon D Mavroudis
Benjamin D Schwartz
Laurel J Mengle-Gaw
Edward C Smith
Jean K Mah
Michela Guglieri
Yoram Nevo
Nancy Kuntz
Craig M McDonald
Mar Tulinius
Monique M Ryan
Richard Webster
Diana Castro
Richard S Finkel
Andrea L Smith
Lauren P Morgenroth
Adrienne Arrieta
Maya Shimony
Mark Jaros
Phil Shale
John M McCall
Yetrib Hathout
Kanneboyina Nagaraju
John van den Anker
Leanne M Ward
Alexandra Ahmet
Michaelyn R Cornish
Paula R Clemens

Document Type

Journal Article

Publication Date

9-13-2018

Journal

Pharmacological research : the official journal of the Italian Pharmacological Society

Volume

136

Inclusive Pages

140-150

DOI

10.1016/j.phrs.2018.09.007

APA Citation

Conklin, L., Damsker, J., Hoffman, E., Jusko, W., Mavroudis, P., Schwartz, B., Mengle-Gaw, L., Smith, E., Mah, J., Guglieri, M., Nevo, Y., Kuntz, N., McDonald, C., Tulinius, M., Ryan, M., Webster, R., Castro, D., Finkel, R., Smith, A., Morgenroth, L., Arrieta, A., Shimony, M., Jaros, M., Shale, P., McCall, J., Hathout, Y., Nagaraju, K., van den Anker, J., Ward, L., Ahmet, A., Cornish, M., & Clemens, P. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.. Pharmacological research : the official journal of the Italian Pharmacological Society, 136 (). http://dx.doi.org/10.1016/j.phrs.2018.09.007

Peer Reviewed

1